Form 8-K - Current report:
SEC Accession No. 0001683168-24-009012
Filing Date
2024-12-27
Accepted
2024-12-27 16:45:08
Documents
16
Period of Report
2024-12-26
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT coeptis_8k.htm   iXBRL 8-K 35645
2 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATION OF INCORPORATION coeptis_ex9901.htm EX-99.1 10864
3 PRESS RELEASE coeptis_ex9902.htm EX-99.2 11958
  Complete submission text file 0001683168-24-009012.txt   286486

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE coep-20241226.xsd EX-101.SCH 3263
5 XBRL DEFINITION FILE coep-20241226_def.xml EX-101.DEF 26557
6 XBRL LABEL FILE coep-20241226_lab.xml EX-101.LAB 36481
7 XBRL PRESENTATION FILE coep-20241226_pre.xml EX-101.PRE 25181
18 EXTRACTED XBRL INSTANCE DOCUMENT coeptis_8k_htm.xml XML 5697
Mailing Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090
Business Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090 724-934-6467
Coeptis Therapeutics Holdings, Inc. (Filer) CIK: 0001759186 (see all company filings)

EIN.: 981465952 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39669 | Film No.: 241586120
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)